Harvard Apparatus Regenerative Technology, Inc. (HRGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350K 700K 1.1M Q4 '14: 93K Q1 '15: 70K Q2 '15: 120K Q3 '15: 155K Q4 '15: 118K Q1 '16: 118K Q2 '16: 73K Q3 '16: 62K Q4 '16: 82K Q1 '17: 82K Q2 '17: 54K Q3 '17: 28K Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q2 '24: 216K Q3 '24: 235K Q4 '24: 430K Q1 '25: 418K Q2 '25: 679K Q3 '25: 743K Q4 '25: 704K Q1 '26: 885K Q2 '26: 982K Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q1 '25 Q2 '26

Gross Profit TTM

-90K -60K -30K 0 30K 60K 90K Q4 '12: 0 Q1 '13: 0 Q2 '13: 0 Q3 '13: 0 Q4 '13: 11K Q1 '14: 22K Q2 '14: 33K Q3 '14: 34K Q4 '14: 45K Q1 '15: 34K Q2 '15: 59K Q3 '15: 77K Q4 '15: -21K Q1 '16: -21K Q2 '16: -73K Q3 '16: -79K Q4 '16: -34K Q1 '17: -34K Q2 '17: -18K Q3 '17: -31K Q4 '17: 0 Q2 '13 Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17

Operating Income TTM

-15M -10M -5M 0 5M 10M 15M Q3 '16: -10.8M Q4 '16: -12.1M Q1 '17: -12.7M Q2 '17: -13.5M Q3 '17: -13.6M Q4 '17: -11.5M Q1 '18: -9.9M Q2 '18: -8.2M Q3 '18: -7.2M Q4 '18: -7.8M Q1 '19: -8.4M Q2 '19: -9M Q3 '19: -9.3M Q4 '19: -8.9M Q1 '20: -8.7M Q2 '20: -7.3M Q3 '20: -5.9M Q4 '20: -5.3M Q1 '21: -4.4M Q2 '21: -4.1M Q3 '21: -3.8M Q4 '21: -8.6M Q1 '22: -9.8M Q2 '22: -10.3M Q3 '22: -10.6M Q4 '22: -6.2M Q1 '23: -6.8M Q2 '23: -8.1M Q3 '23: -8.7M Q4 '23: -9M Q1 '24: -8.1M Q2 '24: -8M Q3 '24: -8.2M Q4 '24: -7.7M Q1 '25: -7.4M Q2 '25: -6.7M Q3 '25: -6.6M Q4 '25: -6.9M Q1 '26: -6.9M Q2 '26: -6.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-15M -10M -5M 0 5M 10M 15M Q3 '16: -10.5M Q4 '16: -11.6M Q1 '17: -12.9M Q2 '17: -13.8M Q3 '17: -14M Q4 '17: -11.9M Q1 '18: -9.6M Q2 '18: -8.1M Q3 '18: -6.9M Q4 '18: -7.5M Q1 '19: -7.9M Q2 '19: -8.3M Q3 '19: -8.6M Q4 '19: -8.3M Q1 '20: -8.4M Q2 '20: -7.2M Q3 '20: -5.4M Q4 '20: -4.9M Q1 '21: -3.7M Q2 '21: -2.9M Q3 '21: -3.1M Q4 '21: -8M Q1 '22: -9.3M Q2 '22: -10.2M Q3 '22: -10.5M Q4 '22: -6.1M Q1 '23: -6.8M Q2 '23: -8.1M Q3 '23: -8.6M Q4 '23: -8.9M Q1 '24: -8.1M Q2 '24: -8M Q3 '24: -8.2M Q4 '24: -7.7M Q1 '25: -7.4M Q2 '25: -6.7M Q3 '25: -6.5M Q4 '25: -6.9M Q1 '26: -6.8M Q2 '26: -6.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 350K 700K 1.1M Q4 '12: 0 Q1 '13: 0 Q2 '13: 0 Q3 '13: 0 Q4 '13: 11K Q1 '14: 23K Q2 '14: 35K Q3 '14: 36K Q4 '14: 48K Q1 '15: 36K Q2 '15: 61K Q3 '15: 78K Q4 '15: 139K Q1 '16: 139K Q2 '16: 146K Q3 '16: 141K Q4 '16: 116K Q1 '17: 116K Q2 '17: 72K Q3 '17: 59K Q4 '17: 0 Q4 '24: 270K Q1 '25: 291K Q2 '25: 580K Q3 '25: 622K Q4 '25: 646K Q1 '26: 819K Q2 '26: 908K Q3 '13 Q3 '14 Q3 '15 Q3 '16 Q3 '17 Q2 '25 Q2 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '16: -7.7M Q4 '16: -9.1M Q1 '17: -9.6M Q2 '17: -11.3M Q3 '17: -12.3M Q4 '17: -11M Q1 '18: -10M Q2 '18: -8.1M Q3 '18: -7.1M Q4 '18: -7.6M Q1 '19: -6.8M Q2 '19: -7.7M Q3 '19: -6.8M Q4 '19: -6.1M Q1 '20: -5.9M Q2 '20: -5M Q3 '20: -4.5M Q4 '20: -4M Q1 '21: -3.5M Q2 '21: -3M Q3 '21: -2.6M Q4 '21: -2.6M Q1 '22: -2.6M Q2 '22: -3.1M Q3 '22: -4.4M Q4 '22: -5.1M Q1 '23: -5.6M Q2 '23: -6M Q3 '23: -7.5M Q4 '23: -6.9M Q1 '24: -6.9M Q2 '24: -6.6M Q3 '24: -4.9M Q4 '24: -4.9M Q1 '25: -4.7M Q2 '25: -4.3M Q3 '25: -4.3M Q4 '25: -3.8M Q1 '26: -4M Q2 '26: -3.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '13: -8M Q1 '14: -7.7M Q2 '14: -8.4M Q3 '14: -8.9M Q4 '14: -9.2M Q1 '15: -9.2M Q2 '15: -8.6M Q3 '15: -8.2M Q4 '15: -7.4M Q1 '16: -8.3M Q2 '16: -7.8M Q3 '16: -7.9M Q4 '16: -9.4M Q1 '17: -9.9M Q2 '17: -11.5M Q3 '17: -12.6M Q4 '17: -11.2M Q1 '18: -10.1M Q2 '18: -8.2M Q3 '18: -7.2M Q4 '18: -7.8M Q1 '19: -6.9M Q2 '19: -7.8M Q3 '19: -6.9M Q4 '19: -6.2M Q1 '20: -6M Q2 '20: -5M Q3 '20: -4.5M Q4 '20: -4M Q4 '23: -7M Q1 '14 Q1 '15 Q1 '16 Q1 '17 Q1 '18 Q1 '19 Q1 '20 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 3.5B 7B 10.5B Q3 '20: 8.9B Q1 '21: 9.4M Q2 '21: 9.7M Q3 '21: 10M Q1 '22: 10.8M Q2 '22: 11.2M Q3 '22: 11.6M Q1 '23: 12.2M Q2 '23: 13.8M Q3 '23: 13.9M Q1 '24: 13.9M Q2 '24: 14.3M Q3 '24: 15M Q1 '25: 15.9M Q2 '25: 15.9M Q3 '25: 17M Q1 '26: 17.6M Q2 '26: 17.6M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q3 '15: -1.38 Q4 '15: -1.19 Q1 '16: -0.98 Q2 '16: -0.71 Q3 '16: -0.70 Q4 '16: -4.44 Q1 '17: -7.09 Q2 '17: -8.86 Q3 '17: -10.34 Q4 '17: -7.04 Q1 '18: -4.77 Q2 '18: -3.38 Q3 '18: -2.09 Q4 '18: -1.77 Q1 '19: -1.53 Q2 '19: -1.35 Q3 '19: -1.31 Q4 '19: -1.21 Q1 '20: -1.13 Q2 '20: -0.90 Q3 '21: -0.31 Q4 '21: -0.78 Q1 '22: -0.89 Q2 '22: -0.97 Q3 '22: -0.99 Q4 '22: -0.55 Q1 '23: -0.59 Q2 '23: -0.66 Q3 '23: -0.68 Q4 '23: -0.68 Q1 '24: -0.59 Q2 '24: -0.58 Q3 '24: -0.58 Q4 '24: -0.53 Q1 '25: -0.48 Q2 '25: -0.41 Q3 '25: -0.39 Q4 '25: -0.41 Q1 '26: -0.40 Q2 '26: -0.39 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.